Find in Library

P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY

oleh: Adrian Minson, Emma Verner, Pratyush Giri, Shu Min Wong, Sumita Ratnasingam, Jason Butler, Wojciech Janowski, Matthew Ku, Chan Cheah, Mark Hertzberg, Kirsten Herbert, Nada Hamad, Costas Yannakou, Paul Neeson, Javad Saghebi, Piers Blombery, Molly Robertson, Lei Shong Lau, Jing Xie, John Seymour, Michael Dickinson